Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting
- Determine the efficacy of adjuvant temozolomide, thalidomide, and celecoxib after
radiotherapy, in terms of time to tumor progression and overall survival, in patients
with newly diagnosed glioblastoma multiforme.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral temozolomide once daily on days 1-5 and oral thalidomide once daily
and oral celecoxib twice daily on days 1-28. Treatment repeats every 28 days for up to 24
courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Patrick Y. Wen, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Massachusetts General Hospital Cancer Center||Boston, Massachusetts 02114|
|Cancer Center at the University of Virginia||Charlottesville, Virginia 22908|
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute||Boston, Massachusetts 02115|
|Brigham and Women's Hospital||Boston, Massachusetts 02115|